|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer(EURTAC):a multicentre,open-label,randomised phase 3 trial显示文摘 | Rosell R Carcereny E Gervais R | 2012 | Lancet Oncol2012，13，3： | 1 |
| 2 | Erlotinib versus standard chemotherapy as first-line treatment for European patients with advaneed EGFR mutation-positive non-small-cell lung cancer (EURTAC) : a multicentre, open-label, randomised phase 3 trial 显示文摘 | Rosell R Carcereny E Gervais R | 2012 | Lancet Oncnl2012，13，3： | 1 |
| 3 | Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial显示文摘 | Rafael Rosell Enric Carcereny Radj Gervais Alain Vergnenegre Bartomeu Massuti Enriqueta Felip Ramon Palmero Ramon Garcia-Gomez Cinta Pallares Jose Miguel Sanchez Rut Porta Manuel Cobo Pilar Garrido Flavia Longo Teresa Moran Amelia Insa Filippo De Marinis | 2012 | Lancet Oncology2012，，3： | 1 |
| 4 | Erlotinib versus stan- dard chemotherapy as first-line treatment for European pa- tients with advanced EGFR mutation-positive non-small cell lung caucer(EURTAC) :a muhicentre,open-label,randomised phase 3 trial显示文摘 | Rosell R Carcereny E Gervais R et a| | 2012 | Lancet Oncol2012，13，3： | 1 |
| 5 | Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer ( EURTAC ) : a multicentre, open-label, randomised phase 3 trial 显示文摘 | Rosell R Carcereny E Gervais R | 2012 | Lancet Oncol2012，13，23： | 1 |
| 6 | Erlotinib versus stand- ard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial显示文摘 | Rosell R Carcereny E Gervais R | 2012 | Lancet Oncol2012，13，3： | 1 |
| 7 | Erlotin ib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC) : a multicentre, open-label, randomised phase 3 trial显示文摘 | ROSELL R CARCERENY E GERVAIS R | 2012 | Lancet Oneol2012，13，3： | 1 |
| 8 | Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small- cell lung cancer (EURTAC): a multi centre,open-label, randomised phase 3 trial 显示文摘 | Rosell R Carcereny E Gervais R | 2012 | Lancet Oncol2012，13，3： | 1 |
| 9 | Erlotinib versus standard chemotherapy as first - line treatment for European patients with advanced EGFR mutation - positive non - small - cell lung cancer (EURTAC) : a multicentre, open - label, randomised phase 3 trial 显示文摘 | Rosell R E Carcereny R Gervais | 2012 | Lancet Oncol2012，13，3： | 1 |
| 10 | Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial显示文摘 | Rafael Rosell Enric Carcereny Radj Gervais Alain Vergnenegre Bartomeu Massuti Enriqueta Felip Ramon Palmero Ramon Garcia-Gomez Cinta Pallares Jose Miguel Sanchez Rut Porta Manuel Cobo Pilar Garrido Flavia Longo Teresa Moran Amelia Insa Filippo De Marinis | 2012 | Lancet Oncology2012，，3： | 1 |
| 11 | Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial显示文摘 | Rosell R Carcereny E Gervais R | 2012 | Lancet Oncol2012，13，3： | 1 |
| 12 | Erlotinib versus standard che- motherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-smallcell lung cancer(EURTAC): a mul- ticentre, opon-label, randomised phase 3 trial 显示文摘 | Rosell R Carcereny E Gervais R | 2012 | Lancet Oncol2012，13，3： | 1 |
| 13 | Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre,open-label,randomised phase 3 trial显示文摘 | Rosell R Carcereny E Gervais R | 2012 | Lancet Oncol2012，13，3： | 1 |
| 14 | Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial显示文摘 | Rafael Rosell Enric Carcereny Radj Gervais Alain Vergnenegre Bartomeu Massuti Enriqueta Felip Ramon Palmero Ramon Garcia-Gomez Cinta Pallares Jose Miguel Sanchez Rut Porta Manuel Cobo Pilar Garrido Flavia Longo Teresa Moran Amelia Insa Filippo De Marinis | 2012 | Lancet Oncology2012，，3： | 1 |
| 15 | Erlotinib versus stand- ard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer(EURTAC):a multicentre,open-label,randomized phase 3 trial显示文摘 | Rosell R Carcereny E Gervais R | 2012 | Lancet Oncol2012，13，3： | 1 |
| 16 | Erlotinib versus standardchemotherapy as first-line treatment for European patients with ad-vanced EGFR mutation-positive non-small-cell lung cancer(EURTAC): a multicentre, open-label, randomised phase 3 trial 显示文摘 | Rosell R Carcereny E Gervais R | 2012 | Oncology2012，13，： | 1 |
| 17 | Erlotinib versus standard chemotherapy as first-line treatment for european patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC) : a multieentre, open-label, randornised phase 3 trial 显示文摘 | RoselI R Carcereny E Gervais R etal | 2012 | The lancet oneology2012，13，3： | 1 |
| 18 | Erlotinib versus standard chemotherapy as first-line treatment for Eu- ropean patients with advanced EGFR mutation-positive non-small-cell lung cancer (EVRTAC):a multicentre, open-label,randomised phase 3 trial 显示文摘 | Rosell R Carcereny E Gervais R | 2010 | Lancet Oncul2010，13，3： | 1 |
| 19 | The epidermal growth factor receptor(EGRF)in lung cancer显示文摘 | Rosell E Carcereny T Morán L | 2015 | Translat Respir Med2015，1，3： | 1 |
| 20 | Erlotinib ver- sus standard chemotherapy as first-line treatment for European pa- tients with advanced EGFR mutation-positive non small-cell lung cancer ( EURTAC ) : A muhicentre, open-label, randomised phase 3 trial 显示文摘 | ROSELL R CARCERENY E GERVAIS R | 2012 | Lancet 0ncol2012，13，3： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员